Almost every patient who receives a coronary stent leaves the hospital with a prescription for two antiplatelet medications rather than one. This combination, known as dual antiplatelet therapy or DAPT, is not an arbitrary precaution — it addresses a specific biological vulnerability that exists in the weeks and months after a stent is placed, before the device becomes fully incorporated into the vessel wall.
Why a Freshly Placed Stent Needs Extra Protection
When a stent is deployed, its metal struts are, for a period, in direct contact with flowing blood rather than fully covered by the vessel's own endothelial lining. This exposed metal surface can promote platelet activation and clot formation — a complication called stent thrombosis — until the process of endothelialization gradually covers the struts with the vessel's natural lining. DAPT works by inhibiting platelet activity from two different angles simultaneously, reducing the likelihood that platelets aggregate and form a clot on the stent surface during this vulnerable window.
The Two Drugs Involved and How They Differ
Aspirin is typically the first agent, inhibiting platelet function through one biochemical pathway, and it is often continued indefinitely after stenting as a long-term cardiovascular protective measure. The second agent is usually a P2Y12 inhibitor — commonly clopidogrel, prasugrel, or ticagrelor — which blocks a different platelet activation pathway. Using both together provides more comprehensive platelet inhibition than either drug alone, which is the core rationale behind dual, rather than single, antiplatelet therapy in the post-stent period.
How Long Is DAPT Typically Prescribed?
Recommended DAPT duration varies based on the specific clinical scenario — whether the stent was placed for stable angina versus during a heart attack, the type of stent used, and the patient's individual bleeding risk versus clot risk profile. Many contemporary guidelines describe DAPT courses ranging from several months to about a year in typical cases, though shorter or longer durations may be appropriate for specific patients, determined by the treating cardiologist rather than a single fixed rule applied to everyone.
Why Stopping Early Can Be Risky
Discontinuing DAPT prematurely, without explicit direction from the treating cardiology team, has been associated in the literature with an increased risk of stent thrombosis, particularly within the first year after stent placement. This is why patients are generally counseled strongly against stopping either medication on their own, and why any upcoming surgery, dental procedure, or new medication that might interact with antiplatelet therapy should be discussed with the cardiology team well in advance whenever possible, rather than adjusted independently.
Balancing Clot Prevention Against Bleeding Risk
DAPT is not without trade-offs: dual antiplatelet inhibition increases bleeding risk compared with a single agent, which is why the prescribed duration reflects an individualized balance between reducing stent thrombosis risk and minimizing bleeding complications. Factors such as advanced age, prior bleeding history, kidney function, and concurrent use of other blood-thinning medications all factor into how a treating physician tailors both the choice of P2Y12 inhibitor and the planned duration of therapy.
What Happens After the DAPT Course Ends
Once the prescribed DAPT period concludes, many patients transition to single antiplatelet therapy, typically continuing aspirin alone indefinitely as part of general cardiovascular risk reduction, though the specific plan is individualized by the treating cardiologist based on ongoing risk assessment. This transition is generally planned in advance rather than left to the patient's own judgment about when to stop the second agent.
Stent Technology and the DAPT Relationship
Stent design characteristics, including strut thickness and coating technology, can influence how quickly a stent endothelializes and, in turn, factor into DAPT duration recommendations discussed in clinical guidelines. INVAMED's coronary artery disease device category includes drug-eluting stent platforms used in contemporary PCI, with specific antiplatelet recommendations following the treating physician's assessment and current clinical guidelines rather than the device specification alone.
What should a patient do if a dentist recommends a procedure while on DAPT?
Patients on DAPT should inform their dentist and consult their prescribing cardiologist before any planned dental procedure, since decisions about temporarily adjusting antiplatelet therapy around a procedure need to weigh bleeding risk against stent thrombosis risk and should never be made unilaterally by the patient.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.